Table 2. Risk of the primary outcome (cardiovascular death, MI, stroke or admission for CHF) on Ramipril and Telmisartan, comparing Asians and Non-Asians in the ONTARGET Study.
Overall | Asian | Non-Asian | p-value† | |
Ramipril | 1412 (16.46%) | 190 (16.07%) | 1221 (16.52%) | 0.775 |
Telmisartan | 1423 (16.66%) | 171 (14.59%) | 1252 (16.99%) | 0.082 |
HR (95% CI)* | 1.01 (0.94–1.09) | 0.92 (0.74–1.13) | 1.03 (0.95–1.11) | 0.305§ |
p-value¶ | 0.004 | 0.046 | 0.020 | - |
*Risk in telmisartan/ramipril group.
p-value (telmisartan vs. ramipril) based on non-inferiority margin 1.13.
p-value (asians vs. non-asians).
p for interaction.